Exploratory subgroup analysis of crizotinib efficacy and safety in asian and non-asian patients with advanced ALK-positive non-small cell lung cancer (NSCLC) enrolled in a global phase II study

Authors
Category Primary study
JournalJournal of Thoracic Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 28bd4ab88f631cc44894afb41d6b1d804838e8ad
First added on: Feb 05, 2025